Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

Blood Cancer J. 2018 Sep 3;8(9):88. doi: 10.1038/s41408-018-0122-3.

¹ Cardiff University, Cardiff, Wales, UK. ottmanno@cardiff.ac.uk.
² University of Turin, Turin, Italy.
³ Imperial College, London, UK.
⁴ Royal North Shore Hospital, Sydney, NSW, Australia.
⁵ Hospital Britanico, Buenos Aires, Argentina.
⁶ Institut Paoli-Calmettes, Marseille, France.
⁷ Washington University School of Medicine, St. Louis, MO, USA.
⁸ The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁹ Winship Cancer Institute, Emory University, Atlanta, GA, USA.
¹⁰ Catholic Hematology Hospital, Seoul St. Mary's Hospital, Leukemia Research Institute, The Catholic University of Korea, Seoul, South Korea.
¹¹ Bristol-Myers Squibb, Princeton, NJ, USA.

No abstract available

Publication types